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Abstract
Recent findings highlight the role of the human gut microbiota in various disorders. 
For example, atherosclerosis frequently seems to be the consequence of gut microbiota–
derived metabolism of some dietary components. Pharmabiotics (i.e., live/dead microbes 
and microbe-derived substances) and probiotics (live microorganisms with a health ben-
efit when administered in adequate amounts) are a means to counteract these deleteri-
ous effects. Among the latter, microbes now being used or, being currently developed, 
are bacteria and eukaryotes (yeasts), so omitting the third domain of life—the archaea, 
despite their unique properties that could be of great interest to human health. Here, we 
promote the idea that some specific archaea are potential next-generation probiotics. This 
is based on an innovative example of the bioremediation of a gut microbial metabolite. 
Indeed, besides the fact that they are archaea (i.e. originating from a domain of life from 
which no pathogens of humans/animals/plants are currently known), they are rationally 
selected based on (i) being naturally human-hosted, (ii) having a unique metabolism not 
performed by other human gut microbes, (iii) depleting a deleterious atherogenic com-
pound generated by the human gut microbiota and (iv) generating a health inert gas.
Keywords: archaea, atherosclerosis, cardiovascular disease, methanogens, Methanom­
assiliicoccales, next-generation probiotics, trimethylamine (TMA), trimethylamine oxide 
(TMAO), trimethylaminuria (TMAU)
1. Introduction
The human intestinal tract is populated with an important number of microbes, which until 
recently, were believed to account for 10-fold more than the number of human cells [1], but 
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now more likely being equivalent [2]. This contributes to the recent view of humans and other 
mammals as being metaorganisms. This microbial community is described as the human gut 
microbiota whose collective genomes form the gut microbiome with about 100-fold the number 
of human genes [3, 4]. It possesses specific functions leading one consider it as an active organ 
which influences multiple functions of the human host [5]. Moreover, its composition is differ-
ent among individuals, resulting and being dependent on various factors: among them, one can 
cite the delivery mode at birth (i.e. vaginal vs. caesarean [6]), genetics [7] and environmental 
factors encompassing drug use and diet [8]. The human gut microbiota is typically composed 
of about 400 different bacterial species (designated as ‘operational taxonomic units’, (OTUs)) 
from a repertory of more than 1.000 OTUs [3, 4, 8, 9]. However, if bacteria are the main constitu-
ents of the gut microbiota, it is well known that besides viruses, the two other domains of life 
(i.e. archaea and eukaryota) are also normal constituents of this microbial community. Archaea 
represent the second most important group of microbes, in number, with a mean of 1.5% of the 
microbiota as recently determined from metagenomics studies on large cohorts [9] (Figure 1).
Among the various roles attributed to the gut microbiota, it acts as a barrier against coloniza-
tion of pathogens and for the development and maintenance of the gut epithelium and its 
structural integrity. Also, it modulates the immune system by the continuous interplay with 
the host immune system. Lastly, it participates in host nutrient metabolism (which is also 
extended to drugs and xenobiotics) by enriching energy and compound retrieval from nutri-
ents. It encompasses, but is not limited, to the synthesis of vitamins and the hydrolysis and 
fermentation of organic matter (e.g. indigestible dietary fibre), leading to the production of 
short-chain fatty acids (SCFA) [10]. The latter accounts for about 5–10% of the overall energy 
harvested by host from diet [11].
Gut microbiota
BACTERIA
98.5 %
ARCHEAEA 1.5 %
EUKARYOTA
mainly methanogens:
Methanobrevibacter smithii
Methanospheara stadtmanae
+  Methanomassiliicoccales
DISEASE
Intesnal disorder
Non-intesnal disorder
Figure 1. The human gut microbiota, its archaeal component and its role in various disorders, sometimes linked to the 
gastrointestinal tract (lower right circle), sometimes to other locations (upper right circle).
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To date, a close link between the gut microbiota and digestive health has been reported and 
documented (Figure 1). It plays an important role in various digestive disorders [12, 13], like 
colon carcinogenesis [14], irritable bowel syndrome (IBS) [15] and inflammatory bowel dis-
eases (IBD) encompassing Crohn’s disease and ulcerative colitis [16]. On first thought surpris-
ing, it is also linked to non-digestive diseases encompassing type 1 and 2 diabetes (T1D and 
T2D) and obesity, as well as conditions such as asthma, autism and depression [10, 13]. It is 
also linked to cardiovascular disease (CVD) which will be described in more detail below. 
Based on these facts, if the microbiota or one of its components is the causing agent of disease, 
maintaining a healthy microbiota or restoring the microbiota from a dysbiosis state to a nor-
mobiosis state should improve health or prevent disorders. Pharmabiotics represent one of 
the ways by which this can be achieved [17].
In the early twentieth century, Eli Metchnikoff proposed the probiotic concept based on 
the observation that consuming host-friendly bacteria as done by Bulgarians, i.e. the bac-
teria found in their yogurts, led to improved health and delayed senility in this popula-
tion [18]. Probiotics are defined by the World Health Organization (WHO), and the Food 
and Agricultural Organization (FAO), as ‘live microorganisms which, when administered 
in adequate amounts, confer a health benefit on the host’. Hence, based on this definition, 
probiotics are microbes that can originate from sources other than food. Based on a rational 
design inferred from the causation of the disorder, in this chapter, we introduce a new stra-
tegic way for discovering new probiotics by highlighting the role that some archaea could 
play in the human gut. Indeed, one group of archaea found in humans can convert a delete-
rious compound of gut bacterial dietary metabolism. This bioremediation leads to methane 
(CH4), which is considered to be inert for health in the human gut. Therefore, these archaea 
could become a source of the next generation pharmabiotics, i.e. archaebiotics, originating 
from the normal composition of the human gut. To date, neither probiotic nor pathogenic 
microorganisms have been determined to exist in the archaeal domain.
2. Diet, gut microbiota and a particularly deleterious plasma compound
Our health is intimately linked to what we eat. The diet itself may contain deleterious com-
pounds; it may also contain initially neutral or even beneficial nutrients that may become 
deleterious after being metabolized by our gut microbiota. Cardiovascular disease (CVD) is 
representative of this two-sided effect. The example below will highlight one of the roles in 
gut microbiota/diet co-participation. CVD is the leading cause of death according to WHO 
(2012), corresponding to more than 17 million deaths every year, about one-third of all deaths. 
A significant part results in the development of atheromatous plaques, an accumulation of 
lipids and adipose tissue (in particular cholesterol), complex carbohydrates/fibrous connec-
tive tissues, minerals and cells (macrophages) on the inner layer of arterial walls. Recognized 
biological risks are hypertension, chronic hyperglycaemia, hyperlipidaemia and overweight/
obesity. Only one fifth of CVD seems to originate from genetic factors, while environment 
alone, or in combination with genetics likely accounts for all other cases [19]. Among envi-
ronmental factors which encompass diet, it is very difficult to determine which nutrient(s) 
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specifically act on atherosclerosis development [20]. However, in 2011, one compound was 
identified in blood that was intimately linked to CVD and whose origin was associated with 
various ingredients and nutrients from diet [21].
2.1. Trimethylamine oxide and atherosclerosis
In 2011, the Stanley Hazen’s laboratory (Cleveland clinic, Cleveland, USA) used a systematic 
approach and analysed plasma metabolites from a learning cohort of 100 patients with vari-
able CVD risks. They succeeded in determining three different molecules that were signifi-
cantly present at higher levels in high-risk subjects; trimethylamine N­oxide (TMAO), betaine 
and choline were linked to CVD [21]. Interestingly, these three compounds may have the same 
alimentary origin that we will discuss below. Results obtained from this learning cohort were 
successfully used on a large validation cohort of 1876 subjects [21]. Also, an extension to 4000 
subjects indicated that plasma TMAO (pTMAO) levels alone were able to predict a 2.5-fold 
increase of major adverse cardiac events (MACE) at 2 years [22]. Moreover, using this high-
value risk factor for prognostics, the authors showed a direct implication of TMAO, or of its 
precursors, in the creation and development of atheromatous plaque. Studies done in vitro 
and with animal models (ApoE−/− mice) showed a role at the intestinal level (alteration of the 
cholesterol reverse transport through biliary acids); at the hepatic level (modification of the 
quantity and composition of the biliary acids pool) and at the arterial level (inflammation, dif-
ferentiation of macrophages into cholesterol containing foam cells that bind to the atheroma-
tous plaque). All of this contributes to atherosclerosis. Moreover, pTMAO enhances platelet 
hyperactivity therefore increasing the thrombosis risk [23], at least in mice.
2.2. Trimethylamine oxide and other disorders
Besides atherosclerosis, trimethylamine oxide (TMAO) has been linked to several other 
important disorders, which does not necessarily mean that TMAO may cause the develop-
ment of the disease. Among them, chronic kidney disease (CKD) and, more specifically, the 
severity of renal dysfunction are strongly associated with the level of pTMAO [24]. This is 
likely attributable to deficiencies in glomerular filtration which leads to altered increase clear-
ance of pTMAO (see Section 2.3.) and accumulation of TMAO in blood [25]. However, there 
are several lines of evidence that pTMAO itself also contributes directly to progressive renal 
fibrosis, at least in animals [26].
Also, type 2 diabetes (T2D) is associated with higher pTMAO levels [27], but until now, it is 
still unclear if this is due to a confounding action with glycaemic control or renal function. 
Interestingly however, various mice T2D models showed that one key liver enzyme implicated 
in the generation of TMA (FMO3, see Section 2.3.) was regulated by insulin [28].
Other disorders analysed so far also encompass colorectal cancer (CRC), for which data 
remain unclear; a study reported the building of epigenetic interaction networks from data of 
interactions between chemicals and genes, between diseases and genes and between proteins 
[29]. This approach was validated by an efficient detection of the known link between TMAO 
and CVD; it also revealed a stronger genetic link between TMAO and CRC as well as one 
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weaker with metabolic syndromes. The link between TMAO and the risk of CRC was also 
established in post-menopausal women [30]. However, all of these results need confirma-
tions/validations, and more importantly, if pTMAO is linked, it is a causing agent.
2.3. Origin of plasma trimethylamine oxide
In order to prevent these disorders, it is essential to determine the plasma origin of the above 
mentioned and linked molecules: betaine, choline, and more specifically, trimethylamine oxide 
(TMAO). People given a specific meal (eggs, see below) showed a rise of TMAO in their plasma 
(pTMAO). Interestingly, after broad-spectrum antibiotic treatment, leading to the eradication of 
as much as possible gut microbes, pTMAO disappeared after the same meal and reappeared 
a few weeks after the cessation of the antibiotics treatment, i.e. when the gut microbiota had 
recovered [22]. Therefore, pTMAO levels are dependent on the nature of the nutrients and of 
the gut microbiota. Nutrients are provided by a broad alimentary range of sources; and, among 
them, TMAO itself which is used as an osmoregulant in many marine life forms and is conse-
quently found in some seafood. Much more studied are choline and phosphatidylcholine (PC, 
also referred as lecithin), which are found in eggs, red meat, fishes, cheese, and some vegetables 
[31, 32]. It also encompasses L-carnitine which is found mainly in red meat and recently in some 
energizing drinks. When ingested, a fraction of dietary choline/PC and L-carnitine reaches gut 
microbes which can metabolize them into trimethylamine (TMA). The metabolic activity of anaer-
obic organisms is still poorly understood and the bacterial enzymes which can convert these com-
pounds into TMA have only recently been determined [33–36]. TMAO is also metabolized into 
TMA in the gut by bacteria. Figure 2 indicates the different pathways that lead to TMA in the gut.
Importantly, the genes encoding these various enzymes are for the most part not specific to a 
bacterial lineage, and horizontal gene transfers have occurred during evolution. As a conse-
quence, based on strictly microbial composition, i.e. 16S amplicon sequencing, this currently 
impairs ways to determine the levels of capability of gut microbiota to deal with these com-
pounds in generating TMA. However, two recent papers showed that it is possible to decipher 
this capability from metagenomics sequencing data (sequencing of whole microbial DNA 
from gut/faecal microbiota) by seeking and counting reads corresponding to marker genes in 
these pathways [37, 38].
The discussed metabolic pathways result in TMA in the gut due to the activity of the micro-
biota. This forms the unique way for the accumulation of TMA in the digestive tract as TMA 
is not ingested by itself through the diet. In fact, this molecule has a very repulsive odour for 
humans as it corresponds to the odour of rotten fish, for which humans are particularly sensi-
tive (see Section 2.4.). TMA is absorbed by the gut epithelium, diffuses and reaches the portal 
vein. It is next oxidized in the liver by monooxygenases, more specifically the hepatic flavin–
containing monooxygenase 3 (FMO3), resulting in pTMAO. Interestingly, this enzyme is not 
only transcriptionally regulated by several elements encompassing sex hormones and bili-
ary acids [39, 40] but also by insulin. pTMAO is excreted via the kidneys into urine. Indeed, 
TMAO has higher renal clearance than urea and creatinine in healthy humans [25]. However, 
as previously mentioned, impaired renal function leads to higher pTMAO levels as observed 
in subjects suffering from chronic kidney disease (CKD) [24].
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2.4. The peculiar case of trimethylaminuria
Trimethylaminuria (TMAU) is a metabolic disorder leading to a TMA/TMAO ratio in urine 
above 5%, indicating a deficiency in liver oxidative processing of TMA [41, 42]. This is likely 
an under-recognized and underdiagnosed disease. It has important psychological and social 
concerns for people suffering from this metabolic disorder. While TMA is partly excreted in 
the urine, it is also eliminated in the breath and sweat; affected people have a rotten-fish odour 
which is very unpleasant. Humans are very sensitive to the odour, probably a remnant of our 
evolution which prevents us from eating spoiled fish. This fish-odour syndrome (the other 
name for TMAU) is caused by a deficiency in functional FMO3. This is mainly a genetic disor-
der (autosomal recessive) corresponding to a rare inborn disease, with about 0.5–1.0% of the 
UK population being heterozygous carriers in the white UK population [43–45]. Therefore, it 
Food
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TMAO
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Figure 2. Origin, fate and implication of trimethylamine TMA and trimethylamine oxide TMAO in various disorders 
through the synthesis of TMA by the human gut microbiota. (1) various kinds of food contain nutrients like TMAO, 
lecithin, choline and L-carnitine. These nutrients come into contact with various gut microbes (2) that are differentially 
present among individuals. Some of these gut bacteria can metabolize these nutrients into TMA with dedicated 
enzymes whose encoding genes are indicated in italics. The TMA generated is absorbed from the gut into the portal 
vein from which it reaches the liver (3). Some people lack an efficient TMA oxidizing activity through the flavin-
containing monooxygenase 3 (upper part, left box), either because of a genetic defect or an acquired one, through hepatic 
dysfunctions/down-regulation of FMO3 expression: this leads to TMA in blood, which can diffuse in any body fluid 
from which it is eliminated. This leads to trimethylaminuria (TMAU) or fish-odour syndrome. In a more general case, 
FMO3 activity is sufficient enough to oxidize TMA into TMAO, which enters the circulation (pTMAO). This compound 
is deleterious and leads through various mechanisms to atherosclerosis and possibly also chronic kidney disease (CKD), 
type 2 diabetes (T2D) and colorectal cancer (CRC) (upper central box).
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can be presumed that about 1 on 40,000 subjects is affected in Great Britain. Also, temporary 
symptoms have been described, resulting in secondary/acquired TMAU: this is due to the 
regulation of the FMO3 (sex hormone dependant), transient liver deficiencies (e.g. viral hepa-
titis), or overload of dietary precursors of TMA by gut microbes [44, 46]
2.5. Strategy to lower plasma trimethylamine oxide
In consequence, lowering plasma trimethylamine oxide (pTMAO) levels is a goal in reaching 
the prevention of, at least partially, the disorders discussed above and more specifically ath-
erosclerosis. Theoretically, three main targets may be considered: first, this can be achieved 
by reducing the precursors of pTMAO that are found in diet. Second, alteration of the gut 
microbiota composition can modify its metabolic behaviour thereby decreasing the synthesis 
of intestinal TMA from dietary precursors. Third, intestinal TMA that has been synthesized 
can be diverted from its hepatic oxidation into TMAO. If we have a more detailed look at each 
of these possibilities, most of them are unrealistic and/or hazardous for humans.
2.5.1. Decreasing TMAO precursors from diet
There are many concerns about trying to limit the contribution of TMAO precursors in diet. 
First, it seems unrealistic for several reasons. As noted previously, there are not one but several 
potential precursors which include lecithin, choline, L-carnitine, and TMAO. Moreover, these 
nutrients are found in a broad diversity of foods, which makes the formulation of ingredients 
and meals difficult; this has also to be considered within cultural/individual backgrounds. 
Also, in this peculiar case where the link between nutrients and pTMAO relies on the gut 
microbiota composition, which is individual specific, it is very difficult to promote some 
foods rather than others knowing that not all individuals would be affected in the same way.
However, the concerns over dietary TMAO precursor removal are frustrating considering 
the main drawback of such a proposition. First, many foods are recognized as health promot-
ing despite the fact that they contain TMAO precursors. For example, fish consumption is 
recommended twice a week for people at risk for coronary heart disease due the presence 
of omega-3 fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
(American Heart Association recommendations) [47]. TMAO and choline/lecithin can be con-
sumed in large amounts via these diets. Second, and much more important, the precursors of 
pTMAO are highly desirable in sufficient amounts for many other roles they play in our body, 
and their limitations could lead inversely to other disorders. As a prime example, such recom-
mendations could lead to choline deficiencies, whose daily intake has been established to be 
between 425 and 550 mg/day, respectively, for women and men in the United States. These 
levels are required to avoid the induction of major cognitive complications and liver disease 
such as hepatic steatosis [48–50].
2.5.2. Decreasing intestinal TMA synthesis
Decreasing TMA synthesis in the gut by the microbiota would result in less TMA reaching the 
liver where it is converted into deleterious pTMAO. This goal may be achieved by several ways, 
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for example, the use of medication, prebiotics, probiotics and faecal microbiota transplanta-
tion (FMT). To our knowledge, there is no evidence, to date, of a probiotic with activity that is 
capable of reducing TMA synthesis in the gut; but, the use of probiotics would be a fine strat-
egy due to its potential for large-scale use. FMT is also very promising as it is used for several 
disorders that are associated by a dysbiosis of the gut microbiota and could be of the highest 
interest in this case. However, this technique is still in its infancy and long-term consequence/
maintenance of a supposed ‘good’ microbiota is unknown. In fact, it seems that such mainte-
nance is rather an ‘ecological agreement’ between the recipient (its physiology/genetics/diet/gut 
microbiota) and the faecal microbial transplant, leading to a mixed microbiota of host/donor. 
It cannot be assumed that microbes leading to TMA will be eradicated or at least drastically 
lowered. Therefore, such an intervention may have to be conducted frequently and at a large 
scale. This approach relies on limited donors, and there is an absence of a biotechnological way 
to amplify such complex microbiota. Also, there is still a lack of an efficient safety procedure 
concerning the donor at the moment of transplantation due to the absence of an efficient way 
to preserve the faecal microbiota; increasing donors and repeating the process could lead to 
an increase of the risk of transmission of infectious diseases by viruses or pathogenic bacteria.
Prebiotics is another way to support beneficial microbes of the gut. It can be noted that compli-
ance to a Mediterranean diet (which is known to decrease CVD risks) leads to lower pTMAO 
levels [51], lending support to the fact that some elements of this kind of diet may contain 
beneficial factors for this purpose. Interestingly, it has been shown recently that resveratrol, 
a natural phytoalexin found notably in grapes and i.e. the Mediterranean diet has a prebiotic 
effect; it remodels the gut microbiota in a beneficial way (encompassing an increase of bile 
acids by de novo synthesis in the liver) and leads to a decrease of pTMAO [52].
Finally, medication is another way by which the gut microbiota may be remodelled. At the 
extreme, the use of antibiotics provides an efficient way to this goal, it is sometimes used to 
treat TMAU patients [42]. This approach proves that TMA synthesis can be efficiently but 
temporarily curtailed; it seems, however, unreasonable to propose the large-scale use of broad 
spectrum antibiotics for this purpose, or its repeated use in affected individuals. Ideally, the 
use of a drug or a combination of drugs would have a more specific action, either by target-
ing bacteria from groups that are known to potentially produce TMA or better by targeting 
the bacterial enzymes involved in TMA synthesis. A very promising drug has been recently 
described, 3,3-dimethyl-1-butanol (DMB) [53]. This compound is a substrate analogue of cho-
line that inhibits TMA-lyases, the bacterial enzyme family that converts several substrates 
into TMA. It is not only active against the synthesis of TMA from choline, but also from 
L-carnitine, at least in some bacterial groups and does not seem to have any lethal effect on 
these bacteria. Therefore, its use should not lead to dramatic changes in the microbiota consti-
tution. Also, interestingly, DMB is naturally found in components of the Mediterranean diet 
(olive oils, red wines) [54]. It remains however to be determined to which extent DMB use will 
decrease pTMAO. In addition, another drug was described a few years ago, already known 
to have clinically cardioprotective effects, supposedly by lowering L-carnitine content in the 
body [55]. This compound, meldonium (also referred as mildronate, formally 3-(2,2,2-tri-
methylhydrazinium) propionate dehydrate), has been shown to lower pTMAO [56] which 
may be due partly on the prevention of bacterial L-carnitine use [57].
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2.5.3. Preventing TMA oxidation into TMAO by the liver
Once TMA has been generated by the microbiota in the gut, one can conceivably try to lower 
its oxidation into pTMAO by host FMO3 enzymes in the liver. Among various solutions, one 
could focus on the inhibition of FMO3. However, this would (i) likely lead to deleterious effects 
by affecting the oxidation/detoxification of other compounds and (ii) allow TMA to enter the 
general circulation at high amounts; symptoms similar to TMAU would appear, i.e. a rotten fish 
odour emanating from the subjects. Therefore, alternatives need to be found that lower TMA 
availability in the gut. While it seems unrealistic to inhibit specifically its absorption by acting 
on epithelial transporters, charcoal is sometimes efficiently used by TMAU patients [42], which 
leads to a decrease of symptoms by increasing TMA excretion in faeces. Therefore, this likely 
lowers TMA in body fluids in these patients, and it can reasonably be assumed that TMA reach-
ing the liver would be lowered in non-TMAU patients, and that, in consequence, pTMAO would 
be lowered. However, it is unclear if this can be applied as a long-term strategy without lower-
ing the absorption of other important intestinal compounds and that could lead to deficiencies.
In summary, it would be of great interest to have a specific agent acting only on intestinal 
TMA. This could be achieved by a biological system able to convert TMA into inert molecules 
in a complex environment (the gut and its microbiota) and without danger to humans. While 
no bacterial species seems suitable, one recently identified group of archaea seems to provide 
all these properties.
3. Human naturally hosted archaea that prevent plasma trimethylamine 
oxide formation
Archaea belong to one of the three domains of life [58]. They are unicellular microorganisms 
distinct from bacteria and eukaryotic cells in regard to evolution and some of their cellular/
molecular processes. For example, their cell membrane has a different composition compared 
to bacteria and eukaryotes [59]. In fact, archaea can be characterized as cells looking like 
bacteria but having cellular, molecular and genetics characteristics of eukaryotes but with 
some differences. One archaeal group recently identified (Lokiarchaeota) has been proposed 
to be at the origin of eukaryote evolutionary divergence, and so, perhaps, a direct ancestor 
of our own cells [60]. Also, the domain Archaea contains microbes with a unique mechanism 
by which they derive energy not found anywhere else in other life forms, i.e. methanogenesis 
[61]. Some methanogenic archaea are found as natural components of the gut microbiota [62], 
where they are principal methane producers. So far also, no pathogens are known among the 
archaea, neither in humans nor in any other animal or plants.
3.1. A recently discovered archaeal lineage primarily recovered from human stools that 
thrived in various environments
About a decade ago, we revealed the existence of unknown archaea in the faecal microbiota of 
some humans [63, 64], with clues that they were methanogens even if belonging to a lineage 
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(Thermoplasmata) with no other known methanogens. Up to now, only one member has been 
isolated in pure culture. Methanomassiliicoccus (Mmc.) luminyensis strain B10 was isolated by 
the joint efforts of two laboratories [65], which lead to the creation of a new methanogenic 
archaeal order named Methanomassiliicoccales [66]. Also, we have currently a highly enriched 
culture with another strain from this order which shows only 89% nucleotide identity for its 16S 
rRNA compared to Mmc. luminyensis B10. It has been named Ca. Methanomethylophilus alvus 
Mx1201. These two strains were obtained from human faecal samples. Phylogenetic data based 
on a DNA survey revealed that this group of methanogens is found in various ecosystems [67, 
68]. These anaerobic environments encompass notably seafloor, wetlands, biogas fermenters, 
etc. but also the gastrointestinal tract of a broad variety of animals. Among them, one can cite 
insects like termites [69], ruminants [68, 70–73], and humans [62–65, 74]. Very interestingly, 
three clusters of Methanomassiliicoccales have been identified [67, 68], reflecting the environmen-
tal source of sampling. One large cluster of neighbouring 16S and/or mcrA (a molecular marker 
of methanogens) sequences corresponds to members almost exclusively retrieved from gastro-
intestinal tracts. Ca. Methanomethylophilus alvus Mx1201 belongs to this cluster, also referred 
as the host-associated- or Gastro-Intestinal Tract (GIT) clade. A second cluster contains mem-
bers retrieved from GIT as well as anaerobic environments like soils or freshwater lakes, etc. 
and is therefore named the mixed cluster, to which Methanomassiliicoccus spp. belongs. Finally, 
the third clade is formed of members exclusively recovered from nondigestive environments, 
at least until now [67, 68].
Still little is known about these archaea, except for the fact that they are methanogens with a 
peculiar metabolism [72, 75, 76]. Their biology is mainly known from genomic studies with 
recent new data (Table 1). Also, microbiological studies have been possible on enrichment 
Name Clade Host/
Environment
Isolate$ TMA use* References
Mmc. luminyensis B10 Mixed Human Y Y (G-AE) Gorlas et al. [93]; 
Borrel et al. [67, 84]; 
Brugère et al. [80]
Ca. Mmp. alvus 
Mx1201
Digestive Human - Y (G-EE) Borrel et al. [75]
Ca. Mmc. intestinalis 
Issoire Mx1
Mixed Human - Y (G) Borrel et al. [67, 84]
Ca. Methanoplasma 
termitum
Digestive Termite - N (G-EE) Lang et al. [77]
RumEn MG1–RumEn 
MG2
Digestive Bovine - Y (G) Sollinger et al. [68]
ISO4-G1 Digestive Sheep - Y (G) Kelly et al. [94]
ISO4-H5 Digestive Sheep - Y (G) Li et al. [95]
Ca. Mmp. sp. 1R26 Digestive Bovine - Y (G) Noel et al. [96]
Notes: $Y refers to a Methanomassiliicoccales strain that has been obtained in pure culture.
*Y and N signify, respectively, that the strain can use (Y) or not use (N) TMA as a methanogenesis substrate, based on 
genomic evidence (G), experimental evidence with enriched culture (EE) or axenic culture (AE).
Table 1.  Available genomic data from Methanomassiliicoccales (end of year 2016).
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cultures with the isolate Mmc. luminyensis B10 [65]. However, the highly enriched culture of 
Ca. Methanomethylophilus alvus Mx1201 from the host-associated clade has already helped 
to characterize one potential health-related metabolic property.
3.2. TMA remediation into methane by some Methanomassiliicoccales
3.2.1. Original methanogens with unique biological property
The biological features, mainly deciphered from genomic data, have revealed several uncom-
mon points. Among them, it is likely that they possess two cellular membranes [77], whose 
composition is typical of other archaea; their phospholipids are indeed composed of L-glycerol 
(instead of D-glycerol as observed in bacterial and eukaryotic phospholipids) and of isopren-
oid side-branch chains (instead of fatty acids as in the two other domains of life). They are 
linked to L-glycerol by an ether bond, instead of an ester bond. However, the cell membranes 
of Mmc. luminyensis are somewhat different from known archaeal membranes. There are 
chemically important nuances; some tetraether lipids (typically two L-glycerols linked by 
isoprenoid chains at both sides and thus not forming a two-layer membrane) are composed 
of one butanetriol or one pentanetriol replacing one L-glycerol [78]. Also, the processes that 
drive energy acquisition from methanogenesis (electron-transport and proton extraction out-
side the cell to be used as a proton motive force linked to ATP synthesis) are different from 
other methanogens [76, 77, 79] and are not currently fully understood.
However, the other important feature is their ability to synthesize and incorporate a spe-
cific unusual amino-acid, pyrrolysine (IUAB nomenclature: Pyl, O) during the translation of 
mRNAs [76, 80]. This incorporation is mediated by a dedicated tRNA, whose particularity, 
besides its size, is to recognize the amber codon UAG, which is usually one of the three non-
sense codons (Figure 3). This ‘22nd amino-acid’ is restricted to specific organisms (metha-
nogens of the taxonomic family Methanosarcinaceae and about 20 different bacterial species) 
and to specific proteins, the methyl transferases that can capture methyl groups in methyl-
amines (i.e. monomethylamine (MMA), dimethylamine (DMA) and trimethylamine (TMA)). 
The reader can find more information about this amino acid and the mechanisms underlying 
its incorporation into proteins, at least in bacteria, in various excellent articles and reviews 
[81–83].
3.2.2. Genomic data indicating a TMA remediation in some but not all members of 
Methanomassiliicoccales
Analysis of the genome of Ca. Methanomethylophilus alvus strain Mx1201 [75] and Ca. Methano-
massiliicoccus intestinalis strain Issoire Mx01 [84] revealed that these Methanomassiliicoccales could 
use methylamines as substrates for their methanogenesis. Comparative genomic analysis with the 
genome of Mmc. luminyensis revealed that it should also be the case for this unique isolate avail-
able at this time [76]. Indeed, all the genes necessary for this metabolism were present, sometimes 
at more than one copy each. Here, we will focus on the genome of Ca. Methanomethylophilus 
alvus strain Mx1201 as it specifically illustrates this point. As shown in Figure 3, the genes encod-
ing methyltransferases and associated proteins, together with the genes necessary for methane 
release (methyl-coM reductase (MCR)) are present; this encompasses genes for the use of MMA 
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(mtm genes), DMA (mtb genes) and TMA (mtt genes). Also, the genes for the use of methanol for 
methanogenesis (mta genes) are present. At the current stage of our investigations, data seem to 
indicate that this species is limited to four possible substrates, namely methanol, MMA, DMA 
and TMA, at least one of them being essential for its life. In fact, all other potential pathways 
for methanogenesis are absent, as genomes sequenced to date show a complete lack of genes 
involved in methanogenesis from CO2 + H2 (hydrogenotrophic methanogenesis) and from ace-
tate (aceticlastic methanogenesis pathways) [68, 76, 77]. Considering methylamines, their use is 
dependant of the ability of the organism to encode Pyl: as previously mentioned, this is the case, at 
least for Ca. Methanomethylophilus alvus, Mmc. luminyensis and Ca. Mmc. intestinalis. However, 
the example of Ca. Methanomethylophilus alvus is very interesting; instead being grouped in one 
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Methyl-coM
genes cluster
Methylamines-use genes cluster
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mtmB x2 mB mtbB
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Pyl tRNA 
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3’
Translation at ribosome
GCC GGU 
TMA-corrinoid methyltransferase
Figure 3. Synthesis mechanism of functional, pyrrolysine-containing TMA-corrinoid methyltransferase. The genetic 
loci of important genes involved in H2-dependant methanogenesis using TMA as a substrate are given in the upper 
part of the figure, taking Ca. Methanomethylophilus alvus Mx1201 as an example. Genes involved in the synthesis 
and translational use of Pyl are indicated by arrows in the upper central box. It encompasses pylB which is genetically 
linked to the genes encoding the methyl-coM reductase (MCR, upper left box), an essential enzyme of methanogenesis 
necessary for the ultimate reaction in any methanogenic pathway. It also encompasses four other genes that neighbour 
genes implicated in the use of methylamines (MMA, DMA and TMA; upper right box). Among them, only genes 
encoding methylamines-corrinoid methyltransferases are shown (mtxB), with a focus (right part) made on the mttB 
CDS (coding DNA sequence) which encodes TMA-corrinoid methyltransferase. A TGA triplet is found in its reading 
frame. Pyrrolysine originates from two lysines using three enzymes encoded by pylB, C and D. A specific Pyl-tRNA 
bearing a CUA anticodon is synthesized by transcription of pylT. It is further charged with pyrrolysine by specific 
enzymatic activity of a dedicated AA-tRNA synthetase encoded by the pylS gene. After transcription of the mttB gene, 
the corresponding mRNA is translated on ribosomes (lower part of the figure). The amber codon UAG, instead of being 
interpreted as a translational stop, is instead recognized by Pyl-tRNA, which leads to the continuation of translation and 
the incorporation of Pyl into the TMA-corrinoid methyltransferase, which is necessary for its biological activity.
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operon as typically found in other Pyl-coding organisms, the pyl genes necessary for synthesis 
and  translational incorporation of Pyl (encompassing the gene encoding the amber suppressive 
tRNA) are scattered among two different loci. The gene pylB which encodes one enzyme neces-
sary for the biosynthesis of Pyl is found in the vicinity of the genes encoding the essential enzyme 
of methanogenesis, MCR, while all other pyl genes are found in the same locus for genes encoding 
methyltransferases for the use of MMA, DMA and TMA. This can be interpreted as an evolution 
which has favoured the linkage of methanogenesis (mcr operon), Pyl encoding property and the 
use of methylamines. This highlights the possible importance of this organism, which lives in the 
human gut, having the ability to use methylamines.
However, the genetic properties for the use of TMA for methanogenesis are not shared by all Methano 
massiliicoccales in humans [38]. Currently, available sequence data of Methanomassiliicoccales 
genomes (end of year 2016) also reveal that one termite-hosted Methanomassiliicoccales does 
not carry the mtt genes for TMA use [77] (Table 1): using enrichment cultures, it showed no 
growth on TMA or DMA (in presence of H2, see below) but was able to grow on methanol and 
MMA (+H2), as predicted from genomic data [77]. So, one question remains: are there some 
Methanomassiliicoccales, preferably isolated from human GITs for which TMA depletion into 
methane is demonstrated?
3.2.3. Experimental evidence that TMA is depleted by some human gut members in presence of H2
In addition to experiments that have been conducted with enriched, nonpure cultures, we have 
been able to show that the isolate from the mixed cluster Mmp. luminyensis was able to use 
methanol as well as MMA and TMA, in presence of H2, to generate methane [80]. Recently, 
experiments were also conducted with Ca. Methanomethylophilus alvus in enrichment cultures 
[38]. The results clearly indicated that this strain, obtained from a human faecal sample, is able 
to use TMA in the presence of H2. Importantly, H2 is a gas which is generated in large amounts 
in the gut by the fermentative metabolism of gut microbes. In order to keep fermentations 
of high yield, without catabolic repression, it needs to be efficiently removed by hydrogeno-
trophs, i.e. mainly hydrogenotrophic methanogens, sulphate reducers and bacteria perform-
ing reductive acetogenesis. Also, analyses of faecal TMA levels have very recently revealed 
significant differences of the presence or the absence of Methanomassiliicoccales [38]: In fact, in 
the Irish ELDERMET cohort consisted of older subjects (>64 years of age) [85, 86], subjects had 
significantly lower TMA concentrations in their stools when harbouring Methanomassiliicoccales 
possessing the genetic behaviour to deplete TMA compared with subjects not carrying 
Methanomassiliicoccales. The significance of this observation was increased when the level of 
potentially TMA using Methanomassiliicoccales was above 108 cells/gram of stool than below [38].
4. Conclusion: archaebiotics, next-generation probiotics?
Through these preliminary data, it is very tempting to propose the use of strains like 
Ca. Methanomethylophilus alvus Mx1201 as next-generation probiotics (Figure 4). That is, a 
periodic ingestion of an archaeal strain in a form and dosage that remains to be determined 
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with the aim of preventing at least CVD by limiting the yield of pTMAO. The mechanism 
relies on the remediation of gut TMA synthesized by gut microbes into a gas (methane) con-
sidered as inert to human physiology. Interestingly, this action should also be effective in 
lowering the symptoms of TMAU. To our knowledge, this is, therefore, a very innovative 
probiotic design considering that
• Archaea, for which no pathogens are known, had not been considered for probiotics use 
until now.
• The microorganisms that fit this use are directly selected from human gut microbial inhab-
itants. They are more prevalent in older people when considering Western countries [38, 
64, 74, 87], but they are also highly prevalent in any age group in one Amazonian tribe, the 
Yanomami hunter-gatherers in Venezuela [88].
• Their selection is based on the knowledge of the mechanisms underlying the pathology 
and is therefore rationally selected first using simple in vitro tests (here, capability of TMA 
usage).
Importantly, despite lacking definitive proof, it has to be noted that the use of TMA by some human-
hosted Methanomassiliicoccales is very likely the metabolism they naturally perform in the gut envi-
ronment. The distribution pattern of the pyl genes in the genome of Ca. Methanomethylophilus 
alvus Mx1201 supports this hypothesis (see above). In fact, it is also suspected that this metabolism 
is the reason for their presence in such an environment; i.e. they occupy an ecological niche that 
other gut members cannot occupy, and they are highly adapted to this environment. Considering 
ARCHAEBIOTICS
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Figure 4. Principle and indications for the use of Methanomassiliicoccales as an archaebiotic for depletion of atherogenic 
trimethylamine TMA. Using the unique property of TMA use by some Methanomassiliicoccales and knowing the 
mechanisms by which pTMAO originates, it is proposed using the human-hosted strain Ca. Methanomethylophilus 
alvus Mx1201 and other rationally selected strains to lower TMA generated by gut microbes directly in the gut/before its 
absorption. This bioremediation would lead to methane which is considered as a heath-inert intestinal gas. This would, 
either limit circulating TMA, therefore lowering symptoms of trimethylaminuria, or limit pTMAO levels, therefore 
preventing, at a minimum, atherosclerosis and chronic kidney disease.
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its importance to resisting this host-derived antimicrobial component, the presence of a bile salt 
hydrolysis gene in Ca. Methanomethylophilus alvus Mx1201 from a bacterial lateral gene transfer 
(LGT) also supports this hypothesis. It should also be considered that this activity has a possible 
role in CVD prevention by lowering circulating cholesterol [89].
In any case, many more experiments are needed to address the question that some Methanomas 
siliicoccales may be efficiently and safely used in humans. In vitro experiments in systems mimicking the 
gut microbial environment [90, 91] which has been shown to efficiently support methanogens [92] 
should help to determine the metabolic behaviour of these archaea as well their interactions with other 
gut microbes. The isolation of a digestive clade member (for example, Ca. Methanomethylophilus 
alvus Mx1201) is therefore an essential and necessary step, before animal and clinical tests.
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